Boston Life Sciences
Boston Life Sciences is a biotechnology company engaged in the research and clinical development of novel diagnostic and therapeutic products for central nervous system diseases. The company is involved in developing imaging agents and nerve growth factors for conditions such as Parkinson's Disease, ADHD, stroke, and spinal cord injury, with a focus on diagnostics and treatment options.
Industries
Nr. of Employees
small (1-50)
Boston Life Sciences
85 Main Street, Hopkinton, MA 01748
Products
Iodine-123 DAT-targeted imaging agent (diagnostic candidate)
Iodine-123–based radiolabeled imaging agent developed to provide an objective diagnostic image of the dopamine transporter for Parkinson's disease and ADHD; clinical program included a Phase III study that was ended early to evaluate the full data set.
Technetium-99–based imaging agent (development candidate)
Technetium-99–based radiopharmaceutical candidate intended for diagnostic imaging of Parkinson's disease and ADHD (preclinical status reported).
Neurotrophic agent candidate for stroke and spinal cord injury (preclinical)
Preclinical candidate described as a nerve growth factor–related therapy intended to support neural recovery in stroke and spinal cord injury.
Small-molecule DAT blocker for Parkinson's disease (preclinical)
Preclinical small-molecule candidate that functions as a dopamine transporter blocker intended for therapeutic evaluation in Parkinson's disease.
Iodine-123 DAT-targeted imaging agent (diagnostic candidate)
Iodine-123–based radiolabeled imaging agent developed to provide an objective diagnostic image of the dopamine transporter for Parkinson's disease and ADHD; clinical program included a Phase III study that was ended early to evaluate the full data set.
Technetium-99–based imaging agent (development candidate)
Technetium-99–based radiopharmaceutical candidate intended for diagnostic imaging of Parkinson's disease and ADHD (preclinical status reported).
Neurotrophic agent candidate for stroke and spinal cord injury (preclinical)
Preclinical candidate described as a nerve growth factor–related therapy intended to support neural recovery in stroke and spinal cord injury.
Small-molecule DAT blocker for Parkinson's disease (preclinical)
Preclinical small-molecule candidate that functions as a dopamine transporter blocker intended for therapeutic evaluation in Parkinson's disease.
Services
Online section providing information about ongoing clinical trials and condition-specific resources for patients, families, and physicians.
Online section providing information about ongoing clinical trials and condition-specific resources for patients, families, and physicians.
Expertise Areas
- Radiopharmaceutical development
- Clinical trial management
- Neurology therapeutics
- Preclinical development
Key Technologies
- Iodine-123 radiolabeling
- Technetium-99 radiolabeling
- Dopamine transporter (DAT) targeting
- Neurotrophic agent development